← Compound index
COMPOUND RECORD / THYMODEPRESSIN

ThymodepressinТимодепрессин

A synthetic two-amino-acid peptide (γ-D-Glu–D-Trp) studied as an immunosuppressant in psoriasis and other immune disorders.

Immune Function
Source linked

What the studies found

Randomized study in people · 2018

Thymodepressin in perennial allergic rhinoconjunctivitis: KI-THYM-001 clinical-study report

Primary nasal-symptom comparison
p=0.6708; no significant between-group difference.Day 16
Selected secondary symptoms and sleep
Some comparisons favored treatment; these do not overturn the neutral primary outcome.
Drug-related adverse events
Reported in both groups; exact counts not extracted; comparison p=1.

The primary nasal-symptom comparison was nonsignificant (p=0.6708); selected secondary symptoms favored Thymodepressin.

Study notes · methods, sources and limitations

Participants or model 72 randomized, 36 per arm; one comparator withdrawal

Design Open randomized active-comparator allergy study; 72 randomized (36/36); one comparator withdrawal. Thymodepressin nasal spray versus standard care.

Later follow-up
Day 47±2, approximately 30 days after therapy.

Important limitations

  • Open active-comparator design; nonsignificance does not establish noninferiority. Report dated 8 October 2018 precedes the listed 20 October study end; signed final version needs authentication. Allergy study, separate from rheumatoid-arthritis protocol ИБХ-ТД01.
  • Superiority and noninferiority are not established. The report-date inconsistency and unsigned fields require a final-version check.

KI-THYM-001, Phase III report; permit 85, 26 February 2018 · Sponsor clinical-study report; not a journal publication

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2014

Evaluation of the efficacy and safety of a Russian selective immune suppressor in treating patients with psoriasis

PASI reduction greater than 75% by day 25
90% with Thymodepressin versus 41% with conventional care

The Russian text reports more than 75% PASI improvement by day 25 in 90% versus 41% in the moderate-disease comparison. Overall favorable outcomes were reported in 100% versus 82.9%.

Study notes · methods, sources and limitations

Participants or model 140 patients with moderate or severe psoriasis

Design 140-patient clinical comparison; the quoted PASI response appears within the moderate-psoriasis discussion.

Important limitations

  • The paper gives these PASI percentages in its discussion of moderate psoriasis. The unclear denominator prevents estimating a response rate across all 140 patients. Blinding and allocation concealment are not established. Concurrent care and treatment selection limit causal attribution. The comparator reflects conventional care at publication, not contemporary targeted biologics.
  • The subgroup denominator is not verified; these percentages must not be described as responses among all 140 participants. Blinding, allocation and concurrent treatment limit attribution.

Clinical Dermatology and Venereology. 2014;12(5):68–74 · Publication record

Original source or citation ↗

Study results and tables ↗

Animal research · 2021

Thymodepressin-Unforeseen Immunosuppressor

Experimental anti-fibrillarin autoantibody responses were lower in selected Thymodepressin groups, including comparisons begun after autoimmunity developed.

Study notes · methods, sources and limitations

Participants or model Small mouse autoimmunity experiments, approximately five to eight animals per group

Important limitations

  • Small induced-animal model, not a human lupus trial. Comparisons against cyclosporine do not establish clinical superiority or equivalent human exposures. The article combines experimental results with historical clinical discussion; those evidence types must remain separate.

Molecules (Basel, Switzerland) · Publication record

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Thymodepressin

Names in this research collection

Timodepressin · γ-D-Glu-D-Trp · D-Glu-D-Trp

Research background

Synthetic γ-D-Glu-D-Trp immunosuppressive dipeptide. Russian reports cover psoriasis, autoimmune cytopenias and myositis; a rheumatoid arthritis trial registration has no verified results.

Autoimmune research: disease-specific findings, immune effects and open questions ↗

Conference sources and research collaborators ↗

Compound class
Synthetic immunosuppressive dipeptide
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Small clinical comparisons and reports; RA protocol is not a result

Study methods

Source-specific designs and limitations below

Independent replication

Related reports are not automatically independent evidence

Source access

Original indexed abstracts and publisher texts; explicit access limits on each record

Safety evidence

Skin-eruption withdrawals reported in historical psoriasis literature; long-term comparative safety remains uncertain

Open a topic for the evidence assessment.

More findings, background and history
RELATED PEPTIDE RESEARCH / UPDATED OCTOBER 2026

Connections in the research

Bestim, Thymogen and Thymodepressin are distinct stereochemical/linkage research objects. Their experimental immune effects should not be combined into a single class claim.

View the peptide family map and sources ↗

What remains unclear

The allergy report found a neutral primary result and gives inconsistent dates. The rheumatoid arthritis registry lists 142 planned participants. Results, psoriasis group counts, withdrawals due to skin eruptions and the full myositis thesis remain to be verified.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 3 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2013 · US8481588B2 · Thymodepressin: monosodium crystal polymorphFormulation · 38 mg recovered from a 50 mg portion, reported 78% yield; XRPD described as essentially form F

Reported findings

The patent reports recovery of defined crystalline forms and conversion of a mixed preparation toward form F.

Selected conversion result
38 mg recovered from a 50 mg portion, reported 78% yield; XRPD described as essentially form FAnalytical/manufacturing observation
Different polymorph example
Form X recovery reported at 60% yield, melting interval 182.3–186.1°CA different crystal form, not a clinical comparator
All reported results, comparisons and limitations →

Formulation. This separate family concerns a particular monosodium crystalline form of the D-amino-acid dipeptide.

A distinct polymorph claim does not establish a different clinical mechanism or make every sodium formulation equivalent.

Publication
US8481588B2 ↗ · 2013-07-09
Earliest priority / filing
2007-02-16 / 2012-06-07
Original applicant / assignee
Apotex Technologies Inc
Indexed status
Expired - Fee Related · checked 2026-11-06
Patent family
39687890 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan

Inventors: Tim Fat Tam; Blaise N'Zemba; Regis Leung-Toung; Yingsheng Wang; Yanqing Zhao; Lily Yu.

US8481588B2 · US8207217B2 · US8592607B2 · US8664262B2 · EP2121727A4 · CN103319393B · CA2579119C · RU2476440C2 · WO2008098355A1

Original patent PDF ↗

Read source review →

2012 · US8138221B2 · Thymodepressin: crystalline salt developmentFormulation · 98.3% HPLC peak-area purity; water content 0.7%

Reported findings

The potassium example reports high analytical purity and low measured water content.

Potassium-salt quality
98.3% HPLC peak-area purity; water content 0.7%Crystalline material characterized by diffraction; not a clinical efficacy endpoint
Preparation recovery
Reported quantitative yield in the potassium exampleManufacturing recovery, not response or bioavailability
All reported results, comparisons and limitations →

Formulation. The disclosure discusses several salts, but the granted US claims narrow to a specified potassium crystal form.

The broader abstract is not the granted claim set; a crystal-form patent does not establish superiority in clinical treatment.

Publication
US8138221B2 ↗ · 2012-03-20
Earliest priority / filing
2006-12-19 / 2007-12-13
Original applicant / assignee
Apotex Technologies Inc
Indexed status
Expired - Fee Related · checked 2026-11-06
Patent family
39535926 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture

Inventors: Tim Fat Tam; Blaise N'Zemba; Regis Leung-Toung; Yingsheng Wang; Yanqing Zhao; Lily Yu.

US8138221B2 · US8735602B2 · EP2121729A4 · KR20090108034A · CN101611050B · AU2007335212B2 · CA2571645A1 · CL2007003680A1 · MX2009006673A · PE20121642A1 · RU2536685C2 · TWI406872B · UA106580C2 · UY30798A1 · WO2008074128A1

Original patent PDF ↗

Read source review →

1998 · US5736519A · Thymodepressin: D-amino-acid dipeptide claimMolecule · Marrow karyocytes >2-fold, CFU-S-8 nearly 3-fold and CFU-S-12 >2-fold higher than cytostatic-only controls

Reported findings

The patent reports context-dependent marrow recovery and improved survival in preclinical models.

Cytopenia experiment
Marrow karyocytes >2-fold, CFU-S-8 nearly 3-fold and CFU-S-12 >2-fold higher than cytostatic-only controlsDay 7 marrow examination24 mice total; 12 received the peptide
Transplant-associated survival
45-day survival described as almost doubled versus control45 daysAbsolute survivor counts and schedule-specific denominators not transcribed
All reported results, comparisons and limitations →

Molecule. Claim 3 identifies the D-glutamyl/D-tryptophan dipeptide associated with Thymodepressin within an immunosuppressive peptide program.

Linkage and stereochemistry distinguish this compound from Thymogen and Bestim; a patent does not demonstrate autoimmune efficacy.

Publication
US5736519A ↗ · 1998-04-07
Earliest priority / filing
1995-06-07 / 1996-06-07
Original applicant / assignee
Individual
Indexed status
Expired - Lifetime · checked 2026-11-06
Patent family
20168146 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Peptide, a method for its preparation and a pharmaceutical composition containing the peptide

Inventors: Vladislav I. Deigin; Andrei Marxovich Korotkov.

US5736519A · EP0832900B1 · JP4082522B2 · CN1154653C · ATE260933T1 · AU724781B2 · BRPI9609235B8 · CA2222296C · CZ287816B6 · DE69631762T2 · DK0832900T3 · ES2217311T3 · HU228461B1 · LT4476B · LV12074B · PT832900E · RU2107692C1 · SK281825B6 · UA48974C2 · WO1996040740A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Experiment described in a patent · 2013

Thymodepressin: monosodium crystal polymorph — US8481588B2

The patent reports recovery of defined crystalline forms and conversion of a mixed preparation toward form F.

Selected conversion result · 38 mg recovered from a 50 mg portion, reported 78% yield; XRPD described as essentially form F · Analytical/manufacturing observation

Study notes and original source
2013Patent / reported experimentsFull text available

Thymodepressin: monosodium crystal polymorph — US8481588B2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu · US8481588B2 · patent family 39687890

The patent reports recovery of defined crystalline forms and conversion of a mixed preparation toward form F.

Results and tables

Reported patent results

Reported findings

The patent reports recovery of defined crystalline forms and conversion of a mixed preparation toward form F.

Solid-form experiments comparing and interconverting monosodium Thymodepressin polymorphs.

Population or model Solid-form experiments comparing and interconverting monosodium Thymodepressin polymorphs.

Results · Crystal-modification examples, including form-F conversion and form-X characterization.
MeasureResultComparison, timing and statistics
Selected conversion result38 mg recovered from a 50 mg portion, reported 78% yield; XRPD described as essentially form FAnalytical/manufacturing observation
Different polymorph exampleForm X recovery reported at 60% yield, melting interval 182.3–186.1°CA different crystal form, not a clinical comparator

Crystal-form recovery and diffraction identity do not establish better autoimmune outcomes, absorption or safety. Polymorphs must not be conflated.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Solid-form experiments comparing and interconverting monosodium Thymodepressin polymorphs.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • A distinct polymorph claim does not establish a different clinical mechanism or make every sodium formulation equivalent.
  • Crystal-form recovery and diffraction identity do not establish better autoimmune outcomes, absorption or safety. Polymorphs must not be conflated.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 2012

Thymodepressin: crystalline salt development — US8138221B2

The potassium example reports high analytical purity and low measured water content.

Potassium-salt quality · 98.3% HPLC peak-area purity; water content 0.7% · Crystalline material characterized by diffraction; not a clinical efficacy endpoint

Study notes and original source
2012Patent / reported experimentsFull text available

Thymodepressin: crystalline salt development — US8138221B2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu · US8138221B2 · patent family 39535926

The potassium example reports high analytical purity and low measured water content.

Results and tables

Reported patent results

Reported findings

The potassium example reports high analytical purity and low measured water content.

Physicochemical development of Thymodepressin salt forms; the granted US claims narrow to a particular potassium crystal.

Population or model Physicochemical development of Thymodepressin salt forms; the granted US claims narrow to a particular potassium crystal.

Results · Example 1: potassium-salt analytical characterization and XRPD figure.
MeasureResultComparison, timing and statistics
Potassium-salt quality98.3% HPLC peak-area purity; water content 0.7%Crystalline material characterized by diffraction; not a clinical efficacy endpoint
Preparation recoveryReported quantitative yield in the potassium exampleManufacturing recovery, not response or bioavailability

Other salts in the description are not automatically within the granted claim. Analytical quality does not establish comparative clinical effectiveness or safety.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Physicochemical development of Thymodepressin salt forms; the granted US claims narrow to a particular potassium crystal.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The broader abstract is not the granted claim set; a crystal-form patent does not establish superiority in clinical treatment.
  • Other salts in the description are not automatically within the granted claim. Analytical quality does not establish comparative clinical effectiveness or safety.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Experiment described in a patent · 1998

Thymodepressin: D-amino-acid dipeptide claim — US5736519A

The patent reports context-dependent marrow recovery and improved survival in preclinical models.

Cytopenia experiment · Marrow karyocytes >2-fold, CFU-S-8 nearly 3-fold and CFU-S-12 >2-fold higher than cytostatic-only controls · 24 mice total; 12 received the peptide · Day 7 marrow examination

Study notes and original source
1998Patent / reported experimentsFull text available

Thymodepressin: D-amino-acid dipeptide claim — US5736519A

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Vladislav I. Deigin, Andrei Marxovich Korotkov · US5736519A · patent family 20168146

The patent reports context-dependent marrow recovery and improved survival in preclinical models.

Results and tables

Reported patent results

Reported findings

The patent reports context-dependent marrow recovery and improved survival in preclinical models.

Thymodepressin-related D-amino-acid peptide mouse studies, including cytostatic-associated cytopenia and allogeneic marrow-transplant observations.

Population or model Thymodepressin-related D-amino-acid peptide mouse studies, including cytostatic-associated cytopenia and allogeneic marrow-transplant observations.

Results · Description: cytopenia experiment, Table 5 narrative and transplant-associated secondary-disease example.
MeasureResultComparison, timing and statistics
Cytopenia experimentMarrow karyocytes >2-fold, CFU-S-8 nearly 3-fold and CFU-S-12 >2-fold higher than cytostatic-only controls24 mice total; 12 received the peptide · Day 7 marrow examination
Transplant-associated survival45-day survival described as almost doubled versus controlAbsolute survivor counts and schedule-specific denominators not transcribed · 45 days

Marrow recovery after injury does not mean general immune stimulation or prove autoimmune treatment benefit. These are animal observations with incomplete quantitative extraction.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Thymodepressin-related D-amino-acid peptide mouse studies, including cytostatic-associated cytopenia and allogeneic marrow-transplant observations.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • Linkage and stereochemistry distinguish this compound from Thymogen and Bestim; a patent does not demonstrate autoimmune efficacy.
  • Marrow recovery after injury does not mean general immune stimulation or prove autoimmune treatment benefit. These are animal observations with incomplete quantitative extraction.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Randomized study in people · 2018

Thymodepressin in perennial allergic rhinoconjunctivitis: KI-THYM-001 clinical-study report

The primary nasal-symptom comparison was nonsignificant (p=0.6708); selected secondary symptoms favored Thymodepressin.

Study notes and original source
2018Randomized trialRussian-language source

Thymodepressin in perennial allergic rhinoconjunctivitis: KI-THYM-001 clinical-study report

Thymodepressin nasal spray versus standard allergy care · Sponsor clinical-study report; not a journal publication

Format: Sponsor-hosted report PDF and companion HTML · Reviewed: Selected report text, pp. 24–25, 60–61 and 75–80. Annexes outside the review.

Triatop — sponsor report · KI-THYM-001, Phase III report; permit 85, 26 February 2018

The primary nasal-symptom comparison was nonsignificant (p=0.6708); selected secondary symptoms favored Thymodepressin.

Results and tables

Reported findings and study design

Open randomized active-comparator allergy study; 72 randomized (36/36); one comparator withdrawal. Thymodepressin nasal spray versus standard care.

Population or model 72 randomized, 36 per arm; one comparator withdrawal

Results · Selected original report text and companion HTML; not a journal paper
MeasureResultComparison, timing and statistics
Primary nasal-symptom comparisonp=0.6708; no significant between-group difference.Day 16
Selected secondary symptoms and sleepSome comparisons favored treatment; these do not overturn the neutral primary outcome.
Drug-related adverse eventsReported in both groups; exact counts not extracted; comparison p=1.
Later follow-upDay 47±2, approximately 30 days after therapy.

Superiority and noninferiority are not established. The report-date inconsistency and unsigned fields require a final-version check.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
72 randomized, 36 per arm; one comparator withdrawal
Source reviewed
Original report text and companion HTML checked. Investigators: A. A. Odegova, A. A. Bagretsova, K. I. Lobanov, A. F. Pyankov and M. G. Omelyanenko.
Study limitations
  • Open active-comparator design; nonsignificance does not establish noninferiority.
  • Report dated 8 October 2018 precedes the listed 20 October study end; signed final version needs authentication.
  • Allergy study, separate from rheumatoid-arthritis protocol ИБХ-ТД01.

Reviewed 2026-11-06.

Read the source ↗

Study involving people · 2002

[Use of thymodepressin for treating autoimmune cytopenia]

The report describes higher hemoglobin in autoimmune hemolytic anemia and higher platelet counts in immune thrombocytopenia, alongside reductions in lymphocyte activation measures.

Study notes and original source
2002Human study · design details unresolvedEnglish abstract

[Use of thymodepressin for treating autoimmune cytopenia]

Vinogradova IuE, Zamulaeva IA, Pavlov VV, Selivanova EI, Deĭgin VI, Smirnova SG, Orlova NV, Saenko AS · Terapevticheskii arkhiv

The report describes higher hemoglobin in autoimmune hemolytic anemia and higher platelet counts in immune thrombocytopenia, alongside reductions in lymphocyte activation measures.

Population / setting
22 patients with autoimmune cytopenias
Source reviewed
Original publication abstract checked; full methodological appraisal pending.
Study limitations
  • Uncontrolled clinical report; changes cannot establish an independent treatment effect.
  • The abstract supplies no reliable comparative effect size or comprehensive safety estimate.

Reviewed 2026-11-05.

Read the source ↗

Observational study · 2013

Current immunopathological therapy of psoriasis

The authors report a 90.4% PASI reduction by day 20 and three-year remission in 70%. The same article describes seven withdrawals following drug-related skin eruptions.

Study notes and original source
2013Uncontrolled human reportRussian-language source

Current immunopathological therapy of psoriasis

E. A. Batkaev, I. A. Chistyakova · Effective Pharmacotherapy. 8/2013

The authors report a 90.4% PASI reduction by day 20 and three-year remission in 70%. The same article describes seven withdrawals following drug-related skin eruptions.

Results and tables

Reported findings and study design

Historical clinical report with 50 course completers and seven reported discontinuations.

Population or model 50 course completers described; seven withdrawals also reported

Results · Source passages checked 5 November 2026; see study record for access and limitations.
MeasureResultComparison, timing and statistics
PASI changeReported 90.4% reduction by day 20
Three-year remissionReported in 70%; follow-up denominator and ascertainment need clarification
Treatment withdrawalsSeven cases after skin eruptions; no adverse-event rate inferred

Completer-only tolerability cannot represent everyone exposed. Historical comparisons and co-treatment prevent a reliable comparative efficacy estimate.

Source for these results ↗ · Reviewed 2026-11-05

Population / setting
50 course completers described; seven withdrawals also reported
Source reviewed
Publisher-hosted Russian article, including efficacy paragraph and discontinuation statement, checked.
Study limitations
  • Historical comparisons and combined care do not yield a randomized treatment effect.
  • The relationship between the 50 completers and seven withdrawals is not fully reconciled; do not calculate an adverse-event rate.
  • No adverse effects among completers does not mean no adverse effects among everyone treated.

Reviewed 2026-11-05.

Read the source ↗

Comparison in people · 2014

Evaluation of the efficacy and safety of a Russian selective immune suppressor in treating patients with psoriasis

The Russian text reports more than 75% PASI improvement by day 25 in 90% versus 41% in the moderate-disease comparison. Overall favorable outcomes were reported in 100% versus 82.9%.

Study notes and original source
2014Human comparative studyRussian-language source

Evaluation of the efficacy and safety of a Russian selective immune suppressor in treating patients with psoriasis

A. A. Kubylinskiy, N. G. Korotkiy, A. A. Tikhomirov, V. Yu. Udzhukhu, N. M. Sharova · Clinical Dermatology and Venereology. 2014;12(5):68–74

The Russian text reports more than 75% PASI improvement by day 25 in 90% versus 41% in the moderate-disease comparison. Overall favorable outcomes were reported in 100% versus 82.9%.

Results and tables

Reported findings and study design

140-patient clinical comparison; the quoted PASI response appears within the moderate-psoriasis discussion.

Population or model 140 patients with moderate or severe psoriasis

Results · Source passages checked 5 November 2026; see study record for access and limitations.
MeasureResultComparison, timing and statistics
PASI reduction greater than 75% by day 2590% with Thymodepressin versus 41% with conventional care

The subgroup denominator is not verified; these percentages must not be described as responses among all 140 participants. Blinding, allocation and concurrent treatment limit attribution.

Source for these results ↗ · Reviewed 2026-11-05

Population / setting
140 patients with moderate or severe psoriasis
Source reviewed
Publisher Russian full text checked. Issue year is 2014; the later website posting date is not a new study date.
Study limitations
  • The paper gives these PASI percentages in its discussion of moderate psoriasis. The unclear denominator prevents estimating a response rate across all 140 patients.
  • Blinding and allocation concealment are not established. Concurrent care and treatment selection limit causal attribution.
  • The comparator reflects conventional care at publication, not contemporary targeted biologics.

Reviewed 2026-11-05.

Read the source ↗

Comparison in people · 2014

Combined therapy of patients with psoriasis

The publication compares combination treatment against Thymodepressin monotherapy and reports categorical skin responses.

Study notes and original source
2014Human comparative studyRussian-language source

Combined therapy of patients with psoriasis

O. V. Degtyarev, V. V. Dumchenko, T. A. Tkachenko, O. V. Zhizhimova, E. G. Bakhmutova, I. N. Selivanova, I. A. Erina · Russian Journal of Skin and Venereal Diseases. 2014

The publication compares combination treatment against Thymodepressin monotherapy and reports categorical skin responses.

Population / setting
72 patients: 42 prednisolone plus Thymodepressin; 30 Thymodepressin alone
Source reviewed
Original publisher article and Russian/English summary checked.
Study limitations
  • No group received neither treatment, so the independent effect of Thymodepressin cannot be estimated.
  • Some response percentages in the English abstract do not match their stated counts; no pooled response estimate is reproduced.

Reviewed 2026-11-05.

Read the source ↗

Randomized study in people · 2017

Clinical evaluation of combined immunosuppressive therapy for psoriasis

This small study compares narrow-band UVB, Thymodepressin and their combination over 21 days, reporting a stronger response with combined care.

Study notes and original source
2017Randomized trialRussian-language source

Clinical evaluation of combined immunosuppressive therapy for psoriasis

V. A. Okhlopkov, O. V. Pravdina, D. S. Melnichenko, E. I. Poleschuk, T. V. Repina · Clinical Dermatology and Venereology. 2017;16(3):64–69

This small study compares narrow-band UVB, Thymodepressin and their combination over 21 days, reporting a stronger response with combined care.

Population / setting
48 patients allocated to three groups of 16; five pregnant patients followed separately
Source reviewed
Original publisher text checked for allocation, separate pregnancy cohort and short-term findings.
Study limitations
  • Only 48 participants belong to the randomized comparison; the five pregnant patients are a separate nonrandomized cohort.
  • Open-label comparison, small groups and short follow-up limit efficacy and safety conclusions.

Reviewed 2026-11-05.

Read the source ↗

Planned study · 2013

Thymodepressin plus methotrexate in rheumatoid arthritis — protocol ИБХ-ТД01

Registry reproduction describes a Phase IV randomized, multicenter, double-blind, placebo-controlled add-on trial with ACR20 as the primary assessment. Listed dates: 4 February 2013 to 30 September 2016.

Study notes and original source
2013Trial protocol / registrationRussian-language source

Thymodepressin plus methotrexate in rheumatoid arthritis — protocol ИБХ-ТД01

· Third-party trial-registry reproduction

Pharma Bio — listed sponsor · Registration No. 77, 4 February 2013; protocol ИБХ-ТД01

Registry reproduction describes a Phase IV randomized, multicenter, double-blind, placebo-controlled add-on trial with ACR20 as the primary assessment. Listed dates: 4 February 2013 to 30 September 2016.

Population / setting
142 planned participants; 14 listed sites; 12-week primary assessment
Source reviewed
Third-party registry reproduction checked; protocol evidence only.
Study limitations
  • ClinLine reproduces a registry record; the original regulatory entry was not independently recovered.
  • Planned enrollment is not confirmed enrollment or completion. No results or primary-endpoint success were verified.
  • Historical listed dates do not establish current trial status.

Reviewed 2026-11-05.

Read the source ↗

Comparison in people · 2008

Idiopathic inflammatory myopathies — Alekseeva doctoral dissertation abstract

The author reports increased proximal arm and leg strength and lower IL-8 and TNF-α production; the IL-10 change was a nonsignificant trend.

Study notes and original source
2008Human comparative studyRussian-language source

Idiopathic inflammatory myopathies — Alekseeva doctoral dissertation abstract

Tatyana M. Alekseeva · Doctoral dissertation author abstract. St. Petersburg, 2008

The author reports increased proximal arm and leg strength and lower IL-8 and TNF-α production; the IL-10 change was a nonsignificant trend.

Results and tables

Reported findings and study design

15 adjunctively treated patients versus 15 symptomatic-care comparators, reported in an author-abstract transcription.

Population or model 30 patients: 15 adjunctive Thymodepressin; 15 symptomatic-care comparators

Results · Source passages checked 5 November 2026; see study record for access and limitations.
MeasureResultComparison, timing and statistics
Proximal arm strengthReported increasep<0.01
Proximal leg strengthReported increasep<0.001
IL-8 / TNF-α productionReported reductionsp<0.01 / p<0.001
IL-10 productionNonsignificant upward trendp=0.08

These are reported pre/post signals, not verified between-group effect estimates. Original full-thesis authentication, allocation and durable outcomes remain unresolved.

Source for these results ↗ · Reviewed 2026-11-05

Population / setting
30 patients: 15 adjunctive Thymodepressin; 15 symptomatic-care comparators
Source reviewed
Author-abstract transcription checked for 15/15 comparison and reported endpoints; original thesis remains a recovery priority.
Study limitations
  • Accessed through a third-party transcription of the author abstract, not an authenticated full dissertation PDF.
  • Small comparison without established randomization or blinding.
  • Reported p values are not effect sizes and do not establish durable disease control.

Reviewed 2026-11-05.

Read the source ↗

Animal research · 2021

Thymodepressin-Unforeseen Immunosuppressor

Experimental anti-fibrillarin autoantibody responses were lower in selected Thymodepressin groups, including comparisons begun after autoimmunity developed.

Study notes and original source
2021Animal / experimentalFull text available

Thymodepressin-Unforeseen Immunosuppressor

Deigin VI, Vinogradova JE, Vinogradov DL, Krasilshchikova MS, Ivanov VT · Molecules (Basel, Switzerland)

Experimental anti-fibrillarin autoantibody responses were lower in selected Thymodepressin groups, including comparisons begun after autoimmunity developed.

Population / setting
Small mouse autoimmunity experiments, approximately five to eight animals per group
Source reviewed
Primary open-access paper checked for animal endpoints and group sizes; not a completed systematic appraisal.
Study limitations
  • Small induced-animal model, not a human lupus trial.
  • Comparisons against cyclosporine do not establish clinical superiority or equivalent human exposures.
  • The article combines experimental results with historical clinical discussion; those evidence types must remain separate.

Reviewed 2026-11-05.

Read the source ↗

Review of earlier studies · 2024

The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples

The review contrasts immune stimulation and suppression across peptide stereochemistry and discusses lymphocyte activation and marrow distribution.

Study notes and original source
2024ReviewFull text available

The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples

V. I. Deigin and colleagues · International Journal of Molecular Sciences. 25(9):5042

The review contrasts immune stimulation and suppression across peptide stereochemistry and discusses lymphocyte activation and marrow distribution.

Population / setting
Review of chiral peptide pharmacology
Source reviewed
Open-access review checked for identity distinctions and mechanistic context.
Study limitations
  • Narrative synthesis is not independent clinical replication.
  • Radiolabel tissue exposure is not proof of intact-peptide targeting or selective suppression of autoreactive cells.

Reviewed 2026-11-05.

Read the source ↗

Animal research · 2005

Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.

Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.

Study notes and original source
2005Animal / experimentalEnglish abstract

Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.

Related L- and D-iEW isomers; preparation equivalence is not inferred

Format: Journal article · Reviewed: Indexed abstract reviewed

O. V. Semina, T. N. Semenets, I. A. Zamulaeva, E. I. Selivanova, Ya. V. Malyutina, Yu. A. Semin, V. I. Deigin, A. S. Saenko · Bulletin of Experimental Biology and Medicine. 140(3):348–351

Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.

Population / setting
Mice; splenic colony-forming, CD34-positive-cell and T-cell assays
Source reviewed
Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
  • Mechanistic interpretation does not establish CD34 as a directly bound receptor.
  • Related-isomer experiments do not prove clinical effects of either marketed preparation.
  • Colony formation is not proof of long-term self-renewing stem-cell expansion.

Reviewed 2026-10-03.

Read the source ↗

Animal research · 2020

Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides.

The later platform paper studies suppressive cyclic derivatives. Opposing experimental effects do not establish a shared receptor or clinical interchangeability.

Study notes and original source
2020Animal / experimentalEnglish abstract

Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides.

Preparation-specific research; no equivalence inferred

Deigin V, Ksenofontova O, Yatskin O, Goryacheva A, Ignatova A, Feofanov A, Ivanov V. · International immunopharmacology

The later platform paper studies suppressive cyclic derivatives. Opposing experimental effects do not establish a shared receptor or clinical interchangeability.

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Animal research · 2009

The effects of the EW--peptide optical and chemical isomers on the hemopoietic stem cells in intact and irradiated mice.

Follow-up record on optical and chemical isomers. No abstract was recovered; overlap with earlier experiments remains unresolved.

Study notes and original source
2009Animal / experimentalBibliographic record

The effects of the EW--peptide optical and chemical isomers on the hemopoietic stem cells in intact and irradiated mice.

Preparation-specific research; no equivalence inferred

Deigin VI, Semenets TN, Zamulaeva IA, Maliutina YV, Selivanova EI, Saenko AS, Semina OV. · Advances in experimental medicine and biology

Follow-up record on optical and chemical isomers. No abstract was recovered; overlap with earlier experiments remains unresolved.

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata only checked via Europe PMC. Original full methods not reviewed. Study type is based on the database record and abstract, where available.
Study limitations
  • Citation only. The preparation and methods are unverified.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Animal research · 2007

Thymodepressin inhibits migration of CD34+ cells from bone marrow in normal and granulocyte CSF-stimulated hemopoiesis.

Mouse CD34-positive cell distribution and adhesion-marker changes suggest altered trafficking. They do not identify a direct molecular receptor or demonstrate human stem-cell expansion.

Study notes and original source
2007Animal / experimentalEnglish abstract

Thymodepressin inhibits migration of CD34+ cells from bone marrow in normal and granulocyte CSF-stimulated hemopoiesis.

Preparation-specific research; no equivalence inferred

Semina OV, Semenets TN, Zamulaeva IA, Selivanova EI, Il'ina TP, Malyutina YV, Semin DY, Deigin VI, Saenko AS. · Bulletin of experimental biology and medicine

Mouse CD34-positive cell distribution and adhesion-marker changes suggest altered trafficking. They do not identify a direct molecular receptor or demonstrate human stem-cell expansion.

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Animal research · 2007

The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice.

Optical configuration, peptide linkage and administration before or after irradiation affected colony-forming responses. Normal marrow and injury recovery are different endpoints.

Study notes and original source
2007Animal / experimentalEnglish abstract

The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice.

Preparation-specific research; no equivalence inferred

Deigin VI, Semenets TN, Zamulaeva IA, Maliutina YV, Selivanova EI, Saenko AS, Semina OV. · International immunopharmacology

Optical configuration, peptide linkage and administration before or after irradiation affected colony-forming responses. Normal marrow and injury recovery are different endpoints.

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Animal research · 2006

Effects of structural and "mixed" isomers of Glu-Trp dipeptide on normal hemopoietic stem cells.

Glu–Trp isomers produced different colony-assay effects depending on stereochemistry and bond position. Results cannot be reduced to a universal L-stimulates/D-suppresses rule.

Study notes and original source
2006Animal / experimentalEnglish abstract

Effects of structural and "mixed" isomers of Glu-Trp dipeptide on normal hemopoietic stem cells.

Preparation-specific research; no equivalence inferred

Semina OV, Semenets TN, Zamulaeva IA, Selivanova EI, Malyutina YV, Saenko AS, Deigin VI. · Bulletin of experimental biology and medicine

Glu–Trp isomers produced different colony-assay effects depending on stereochemistry and bond position. Results cannot be reduced to a universal L-stimulates/D-suppresses rule.

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Animal research · 2005

[Thymodepressin protects murine bone marrow CFU-S from the hyperthermic damage].

Experiments found differing heat responses in normal marrow precursors and tumor model cells. Heating cells to 43°C does not demonstrate whole-body heat tolerance or occupational protection.

Study notes and original source
2005Animal / experimentalEnglish abstract

[Thymodepressin protects murine bone marrow CFU-S from the hyperthermic damage].

Preparation-specific research; no equivalence inferred

Semenets TN, Semina OV, Deĭgin VI, Maliutina IaV, Saenko AS. · Radiatsionnaia biologiia, radioecologiia

Experiments found differing heat responses in normal marrow precursors and tumor model cells. Heating cells to 43°C does not demonstrate whole-body heat tolerance or occupational protection.

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Animal research · 2001

Synthetic peptide thymodepressin promoted take of transplanted hemopoietic precursor cells in the bone marrow of irradiated mice.

A mouse transplantation experiment measured donor-cell colony formation following pretreatment and irradiation. The proposed marrow-microenvironment mechanism remains a hypothesis.

Study notes and original source
2001Animal / experimentalEnglish abstract

Synthetic peptide thymodepressin promoted take of transplanted hemopoietic precursor cells in the bone marrow of irradiated mice.

Preparation-specific research; no equivalence inferred

Semina OV, Semenets TN, Poverennyi AM, Deigin VI. · Bulletin of experimental biology and medicine

A mouse transplantation experiment measured donor-cell colony formation following pretreatment and irradiation. The proposed marrow-microenvironment mechanism remains a hypothesis.

Results and tables

Reported findings and study design

Animal marrow-transplant experiment; Thymodepressin at 48, 24 and 2 hours before irradiation/transplantation.

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Day-9 splenic colonies after allogeneic transplantFivefold increase versus control
Colony assessmentDays 9 and 12

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Animal research · 2000

[The synthetic peptide D-(iEW) (thymodepressin) protects bone marrow CFU-S from ionizing radiation exposure].

Pre-irradiation treatment reduced the cycling fraction of marrow colony-forming cells and was associated with later colony recovery. Timing and model are essential to interpretation.

Study notes and original source
2000Animal / experimentalEnglish abstract

[The synthetic peptide D-(iEW) (thymodepressin) protects bone marrow CFU-S from ionizing radiation exposure].

Preparation-specific research; no equivalence inferred

Semina OV, Deĭgin VI, Semenets TN, Beziaev GP, Poverennyĭ AM. · Radiatsionnaia biologiia, radioecologiia

Pre-irradiation treatment reduced the cycling fraction of marrow colony-forming cells and was associated with later colony recovery. Timing and model are essential to interpretation.

Results and tables

Reported findings and study design

Animal marrow-radiation experiment; Thymodepressin two days before 4 Gy irradiation.

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Marrow CFU-S recoveryThree- to fivefold the irradiated-control value

A hematopoietic colony endpoint, not a general human radiation-protection estimate.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Review of earlier studies · 2023

Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides

Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.

Study notes and original source
2023ReviewFull text available

Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides

Defined synthetic peptide / analogue

Vladislav Deigin, Natalia Linkova, Olga Volpina · International Journal of Molecular Sciences 24(17):13534

Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.

Population / setting
Source-specific experimental population
Source reviewed
Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.
Study limitations
  • Independent replication and full risk-of-bias appraisal remain unresolved.
  • No personalized treatment or safety conclusion follows from this record.

Reviewed 2026-10-02.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗